Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.

Mesa RA

Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.

Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR

Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia.

Mesa RA, Hanson CA, Li CY, Yoon SY, Rajkumar SV, Schroeder G, Tefferi A

Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia.

Tefferi A, Mesa RA, Gray LA, Steensma DP, Camoriano JK, Elliott MA, Pardanani A, Ansell SM, Call TG, Colon-Otero G, Schroeder G, Hanson CA, Dewald GW, Kaufmann SH

Thalidomide treatment in myelofibrosis with myeloid metaplasia.

Elliott MA, Mesa RA, Li CY, Hook CC, Ansell SM, Levitt RM, Geyer SM, Tefferi A

Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study.

Steensma DP, Mesa RA, Li CY, Gray L, Tefferi A

Adverse events after imatinib mesylate therapy.

Elliott MA, Mesa RA, Tefferi A

A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies.

Rajkumar SV, Mesa RA, Tefferi A

Palliative splenectomy in myelofibrosis with myeloid metaplasia.

Mesa RA, Tefferi A

A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia.

Mesa RA, Tefferi A, Elliott MA, Hoagland HC, Call TG, Schroeder GS, Yoon SY, Li CY, Gray LA, Margolin S, Hook CC